2012
CREBZF, a novel Smad8-binding protein
Lee J, Lee G, Kwon S, Jeong J, Ha Y, Kim W, Kim I. CREBZF, a novel Smad8-binding protein. Molecular And Cellular Biochemistry 2012, 368: 147-153. PMID: 22707059, DOI: 10.1007/s11010-012-1353-4.Peer-Reviewed Original ResearchConceptsSmads 1Novel SmadTranscription factorsBMP-6Basic region-leucine zipper (bZIP) transcription factorsBone morphogenetic protein (BMP) pathwayRegulation of SmadTwo-hybrid screeningModulation of BMPBMP response elementZipper transcription factorTGF-β signal pathwayR-SmadsReceptor SmadsBMP pathwaySecondary messengersPromoter activityLigand bindingProtein pathwayResponse elementProstate cancer cell linesCell growth inhibitionHuman prostate cancer cell linesSmadSignal pathway
2005
Transforming Growth Factor-β: Biology and Clinical Relevance
Kim I, Kim M, Kim S. Transforming Growth Factor-β: Biology and Clinical Relevance. BMB Reports 2005, 38: 1-8. PMID: 15715939, DOI: 10.5483/bmbrep.2005.38.1.001.Peer-Reviewed Original Research
2004
Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy
Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63: 1191-1197. PMID: 15183988, DOI: 10.1016/j.urology.2003.12.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDisease ProgressionFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedMultivariate AnalysisNeoplasm StagingProstateProstatectomyProstate-Specific AntigenProstatic HyperplasiaProstatic NeoplasmsReceptors, Transforming Growth Factor betaTransforming Growth Factor betaTransforming Growth Factor beta1ConceptsPlasma TGF-beta1 levelsTGF-beta1 levelsAbnormal expressionTGFbeta-RIITGFbeta-RIBiochemical progressionRadical prostatectomyProstate cancerPathologic Gleason scoreSeminal vesicle involvementSurgical margin statusProstate cancer featuresTissue expressionGrowth factor-β1TGF-beta1 overexpressionConsecutive patientsExtracapsular diseaseMargin statusPathologic featuresGleason scoreBlood levelsLoss of expressionPrognostic markerImmunohistochemical stainingFactor-β1
2003
Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.
Kim I, Lee D, Lee D, Kim B, Kim H, Leach F, Linehan W, Morton R, Kim S. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clinical Cancer Research 2003, 9: 6046-51. PMID: 14676131.Peer-Reviewed Original ResearchBlotting, NorthernBone Morphogenetic Protein 6Bone Morphogenetic Protein Receptors, Type IIBone Morphogenetic ProteinsCarcinoma, Renal CellDown-RegulationHumansImmunoblottingImmunoenzyme TechniquesKidney NeoplasmsProtein Serine-Threonine KinasesReceptors, Cell SurfaceReverse Transcriptase Polymerase Chain ReactionTransforming Growth Factor betaTumor Cells, Cultured
2002
The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor-β Signaling by Blocking Binding of the Smad Complex to Its Target Sequence*
Lee D, Kim B, Kim I, Cho E, Satterwhite D, Kim S. The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor-β Signaling by Blocking Binding of the Smad Complex to Its Target Sequence*. Journal Of Biological Chemistry 2002, 277: 38557-38564. PMID: 12145312, DOI: 10.1074/jbc.m206786200.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell LineCyclin-Dependent KinasesDNADNA-Binding ProteinsFemaleGenes, ReporterHumansOncogene Proteins, ViralPapillomaviridaeProtein BindingSignal TransductionSmad ProteinsTrans-ActivatorsTranscription, GeneticTransforming Growth Factor betaTransforming Growth Factor beta1Uterine Cervical NeoplasmsConceptsHuman papillomavirus (HPV) oncoprotein E7HPV-positive cellsCervical cancerTGF-beta signalingSuppression of SmadConfocal microscopic studiesE7 oncoproteinsOncoprotein E7Growth inhibitory activitySmad transcriptional activityHPVE7Inhibitory activityMicroscopic studyTranscriptional activityDNA synthesisSmadSmad proteinsSignalingEtiologyCancerInfectionPRB
2001
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma
Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92: 2985-2992. PMID: 11753975, DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsMuscle-invasive transitional cell carcinomaTransitional cell carcinomaT1 transitional cell carcinomaPreoperative plasma levelsPlasma TGFDisease recurrenceIndependent predictorsLymph nodesClinical outcomesPlasma levelsBladder carcinomaGrowth factorDisease-specific mortalityDisease-specific survivalRegional lymph nodesSubgroup of patientsStrong independent predictorGrowth factor-β1Intravesical immunoCarcinoma metastaticLymphovascular invasionSpecific survivalRadical cystectomyPathologic featuresCell carcinomaPredictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder
Kim J, Shariat S, Kim I, Menesses‐Diaz A, Tokunaga H, Wheeler T, Lerner S. Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001, 92: 1475-1483. PMID: 11745225, DOI: 10.1002/1097-0142(20010915)92:6<1475::aid-cncr1472>3.0.co;2-x.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Transitional CellCystectomyHumansImmunohistochemistryNeoplasm InvasivenessNeoplasm StagingReceptors, Transforming Growth Factor betaTransforming Growth Factor betaUrinary Bladder NeoplasmsConceptsTransitional cell carcinomaBladder transitional cell carcinomaInvasive tumor stageOverexpression of TGFDisease progressionIndependent predictorsCell carcinomaTumor stageLoss of expressionTGF betaGrowth factorDisease-specific survivalAltered expressionExpression of TGFGrowth factor-β1Lymphovascular invasionRadical cystectomySpecific survivalClinical outcomesCystectomy specimensUrinary bladderImmunohistochemical stainingBlinded fashionFactor-β1Predictive valuePreoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.Peer-Reviewed Original ResearchConceptsProstate cancer metastaticPlasma TGFPreoperative plasma levelsRegional lymph nodesRadical prostatectomyCancer metastaticPSA progressionLymph nodesGleason sumPlasma levelsGrowth factorLocal-only failureOccult metastatic diseasePathologic Gleason sumPostoperative multivariate analysisOrgan-confined diseaseSurgical margin statusLymph node metastasisBiopsy Gleason sumRadical prostatectomy patientsProstate cancer invasionMetastatic diseaseBone metastasesConsecutive patientsMargin status
1998
Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1
Rohlff C, Blagosklonny M, Kyle E, Kesari A, Kim I, Zelner D, Hakim F, Trepel J, Bergan R. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. The Prostate 1998, 37: 51-59. PMID: 9721069, DOI: 10.1002/(sici)1097-0045(19980915)37:1<51::aid-pros8>3.0.co;2-b.Peer-Reviewed Original ResearchConceptsProstate cancer cell growthCancer cell growthProtein kinase CHormone-refractory prostate cancerProstate cancer cell growth inhibitionGrowth inhibitionInhibition of PKCG1/S phase cell cycle arrestTamoxifen-mediated growth inhibitionCancer cell growth inhibitionProstate cancer cellsPhase cell cycle arrestDU145 prostate cancer cellsS-phase cell cycle arrestRetinoblastoma protein levelsFlow cytometric analysisP21WAF1/CIP1Cell growth inhibitionTamoxifen treatmentCell cycle arrestCell growthProstate cancerKinase CCytometric analysisWestern blotThe Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP
Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP. Experimental Cell Research 1998, 241: 151-160. PMID: 9633523, DOI: 10.1006/excr.1998.4034.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IDihydrotestosteroneGene ExpressionHumansMaleProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaRNA, MessengerSensitivity and SpecificitySignal TransductionTransforming Growth Factor betaTumor Cells, CulturedConceptsHuman prostate cancer cell linesCompetitive quantitative RT-PCRProstate cancer cell linesType II receptorLNCaP cellsII receptorsWestern blot analysisQuantitative RT-PCRCancer cell linesTGF-beta signalingALK-5RT-PCRALK-1Androgen-responsive human prostate cancer cell lineGrowth factor-β receptor type IType II receptor mRNAReceptor type IConcentrations of dihydrotestosteroneTGF-β1 signalingCell linesBlot analysisType INM dihydrotestosteroneReceptor mRNADihydrotestosterone
1997
Prostatic ductal system in rats: Tissue‐specific expression and regional variation in stromal distribution of transforming growth factor‐β1
Nemeth J, Sensibar J, White R, Zelner D, Kim I, Lee C. Prostatic ductal system in rats: Tissue‐specific expression and regional variation in stromal distribution of transforming growth factor‐β1. The Prostate 1997, 33: 64-71. PMID: 9294629, DOI: 10.1002/(sici)1097-0045(19970915)33:1<64::aid-pros11>3.0.co;2-j.Peer-Reviewed Original ResearchConceptsProstatic ductal systemDuctal systemRat ventral prostateAlpha-smooth muscle actin-positive stromal cellsVentral prostateProstatic smooth muscleGrowth factor-β1Stromal-epithelial interactionsEpithelial cell deathNormal rat prostateCell deathEpithelial cell compartmentStromal cell fractionImmunohistochemical stainingSmooth muscleStromal distributionFactor-β1Rat prostateGrowth regulatory roleNormal prostateProximal ductPercoll gradient centrifugationProstateStromal cellsRT-PCR analysis
1996
Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP
Kim I, Kim J, Zelner D, Ahn H, Sensibar J, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996, 137: 991-999. PMID: 8603613, DOI: 10.1210/endo.137.3.8603613.Peer-Reviewed Original ResearchMeSH KeywordsAndrogensBase SequenceCell DivisionDose-Response Relationship, DrugHumansMaleMolecular Sequence DataProstatic NeoplasmsSignal TransductionTransforming Growth Factor betaTumor Cells, CulturedConceptsDoses of dihydrotestosteroneProstatic cancer cell linesLNCaP cellsCancer cell linesTGF-beta1 messenger RNART-PCRCompetitive quantitative RT-PCRTGF-beta1 proteinDose-dependent increaseGrowth arrestEnzyme-linked immunoadsorbent assayCell linesTGF-beta1 neutralizing antibodyActivation of latentDose-response curveMessenger RNALNCaP proliferationQuantitative RT-PCRWestern blot analysisNeutralizing antibodiesLinear dose-response curveHigh doseTGF-beta1Immunoadsorbent assayGrowth factorModulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone
Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone. Experimental Cell Research 1996, 222: 103-110. PMID: 8549651, DOI: 10.1006/excr.1996.0013.Peer-Reviewed Original ResearchMeSH KeywordsBinding, CompetitiveCell CountCell DivisionDihydrotestosteroneDNA, NeoplasmHumansMalePromoter Regions, GeneticProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTranscriptional ActivationTransforming Growth Factor betaTumor Cells, CulturedConceptsTGF-beta receptor type IILNCaP cellsReceptor type IIAndrogen-responsive prostate cancerCharcoal-stripped fetal bovine serumEffect of dihydrotestosteroneGrowth factor-β1Type II TGF-β receptorProstate cancer cellsGrowth inhibitory effectsTGF-β receptorWestern blot analysisDHT concentrationsPresent studyType IIModulation of sensitivityProstate cancerAndrogenic conditionsFactor-β1DihydrotestosteronePotential physiological regulatorsInhibitory effectGene transcriptional activityCancer cellsPhysiological regulatorGenetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.
Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 1996, 56: 44-8. PMID: 8548772.Peer-Reviewed Original ResearchConceptsProstate cancer cell linesLNCaP cellsProstate cancer cellsType I receptorT beta RCancer cell linesI geneDU145 cellsGenetic changesTGF-beta receptor type III receptorTGF-beta receptor expressionGrowth factor beta 1Beta RCancer cellsHuman prostate cancer cellsProliferation of PC3TGF-beta signalsBlot analysisReceptor type IICell linesDose-dependent mannerSouthern blot analysisType I geneType II receptor